AllAnalyst Report
Morningstar•May 11, 2021
Morningstar•May 11, 2021Viatris Inc.: Stable First Quarter for Viatris Propped Up by Biosimilars
Summary
The new entity will largely be led by Pfizer executives and will be registered in Delaware. The new entity is anticipated to leverage the stand-alone Mylan infrastructure consisting of roughly 55 manufacturing and research and development facilities and that were largely acquired, including Matrix Laboratories and the generics business of Germany-based Merck KGaA. The combined portfolio will consist of the mature Upjohn drugs with notably better economics and Mylan's portfolio of more than 7,500 generic, specialty, and over-the-counter active ingredients and m
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Market Digest: BX, GE, GPC, NUE, SAP, RTX, BMI, MSCI, CFGApr 24, 2024 •
SAP, CFG, BX, RTX, MSCI, GPC, GE, BMI, NUE
- Analyst Report: RTX Corp.Apr 24, 2024 •
RTX
- Analyst Report: RTX CorporationApr 24, 2024 •
RTX
- LUMN: What does Argus have to say about LUMN?Apr 24, 2024 •
LUMN
- KD: Raising target price to $22.00Apr 24, 2024 •
KD
Analyst Profile
Damien Conover
Sector DirectorDamien Conover, CFA, is director of healthcare equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He is also director of equity strategy, responsible for helping to shape, package, and surface research based on Morningstar's investment philosophy by working closely with the firm's North American sector strategists and directors.Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.Conover holds bachelor's and master's degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.